The objective of this Phase 1 study is to determine the safety and tolerability of OLX10212 in patients with advanced AMD at multiple sites in the US.
Paliperidone Extended-Release Tablets (RLD Invega) had estimated annual sales of USD 152 million in the U.S
Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia
An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
It is only the second healthcare provider in the world to attain the Stage 6 DIAM certification.
Revenues from operations for the full year ended March 31, 2022 stood at Rs. 590.05 crore as compared to Rs. 449.82 crore in FY21
The capacity addition in Suwa is part of Saint-Gobain Life Sciences ongoing investment plan to globally expand production capacity for its products and services used throughout the bioprocessing industry
Tislelizumab is now approved in nine indications in China
TAK-003 is currently undergoing regulatory review for potential licensure in both the European Union
New Director supports NASDAQ rule on diversity
Subscribe To Our Newsletter & Stay Updated
